Pharmacology, Toxicology and Pharmaceutical Science
Voriconazole
100%
Therapeutic Drug Monitoring
78%
Invasive Aspergillosis
77%
Inflammation
58%
Posaconazole
56%
Pyrrole
56%
Prospective Study
47%
Aspergillus
30%
Aspergillus fumigatus
26%
Antiinfective Agent
23%
Thrombocytopenia
22%
Hematologic Disease
22%
Mycosis
21%
Infection
20%
C Reactive Protein
20%
Mucosa Inflammation
18%
Dasatinib
18%
Ruxolitinib
18%
Ganciclovir
18%
Clinical Trial
18%
Cobicistat
18%
Myelofibrosis
18%
Prevalence
18%
Avapritinib
18%
Intestine Flora
18%
Ponatinib
18%
Cmin
18%
Bioavailability
18%
Systemic Mastocytosis
18%
Antifungal Agent
18%
Disease
15%
Adverse Event
13%
Triazole
12%
Fluconazole
10%
Ciprofloxacin
9%
Citrulline
9%
Galactomannan
7%
Neutropenia
7%
Observational Study
6%
Pharmacokinetics
6%
Therapeutic Window
5%
Medicine and Dentistry
Systemic Mastocytosis
75%
Systemic Mycosis
60%
Invasive Aspergillosis
56%
Pyrrole
51%
Mastocytosis
37%
Positron Emission Tomography-Computed Tomography
37%
Aspergillus
27%
Aspergillus fumigatus
24%
Overall Survival
23%
Polymerase Chain Reaction
22%
Acute Myeloid Leukemia
22%
Hematologic Malignancy
22%
Sulfhemoglobinemia
22%
Prevalence
22%
Fluorodeoxyglucose F 18
21%
Positron Emission Tomography
21%
Hematology
21%
Diagnosis
20%
Systematic Review
18%
Organomegaly
18%
Mycosis
18%
Antiinfective Agent
18%
Core Binding Factor
18%
Lung Lavage
18%
Multiple Organ Dysfunction Syndrome
18%
Treatment Response
18%
Avapritinib
18%
Polymerase Chain Reaction
18%
Transplantation
18%
Intensive Care
18%
Interim Analysis
18%
Urticaria Pigmentosa
14%
Infection
13%
Lymphadenopathy
12%
Anatomy
12%
Hazard Ratio
12%
Antifungal Agent
12%
Adverse Event
11%
Fungal Infection
11%
Antifungal Therapy
10%
Metabolism
10%
Tryptase
8%
Triazole
8%
Mast Cell
7%
Arm
7%
Neutropenia
7%
Bone Marrow Biopsy
7%
Nuclear Medicine
6%
Survival Rate
6%
Disease Exacerbation
6%
Keyphrases
Systemic Mastocytosis
53%
Voriconazole
37%
Invasive Fungal Infection
37%
Mastocytosis
26%
Competence Networks
23%
Cyp51A mutations
22%
Adult Patients
20%
18F-FDG PET-CT
18%
Mastocytosis in the Skin
18%
Fungal Infection
18%
Hospitalized Patients
18%
Positron Emission Tomography
18%
Core-binding Factor
18%
Treatment Monitoring
18%
Acute Myeloid Leukemia
18%
Severe Inflammation
18%
Metabolism
18%
Exposure Outcome
18%
Poor Risk
18%
Organomegaly
18%
Azole Resistance
18%
Prognostic Impact
18%
Reaction-based
18%
Polymerase Chain Reaction
18%
Aspergillus
18%
Clinical Impact
18%
Invasive Aspergillosis
18%
Avapritinib
18%
Resistance Detection
18%
Multicenter Cohort Study
18%
Bronchoalveolar Lavage Fluid
15%
Overall Survival
14%
Cutaneous Mastocytosis
14%
Trough Concentration
13%
Hazard Ratio
12%
Lymphadenopathy
12%
Risk Score
9%
ISM
9%
Polymerase Chain Reaction Assay
9%
Inflammation
8%
Fecal Swab
7%
Bone Marrow Biopsy
7%
New Occurrence
6%
Fumigatus
6%
Azole-resistant
6%
Treatment Failure
6%
Fluids Samples
6%
Disease Progression
6%
Computed Tomography
5%
High Mortality
5%
